Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Korosho to Reorganize PFSB
October 7, 2002
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
October 7, 2002
-
ARCHIVE Mr Miyauchi Criticizes Korosho for Its Opposition to Deregulation
October 7, 2002
-
ARCHIVE Nippon Keidanren Calls For Simplification of Application for Medical Devices
October 7, 2002
-
ARCHIVE PFSB to Accelerate Introduction of Fast-Track System
October 7, 2002
-
ARCHIVE Olympus Sets Up Marketing Subsidiary in Sao Paulo
October 7, 2002
-
ARCHIVE Drugs for 21st Quality Reevaluation Announced
October 7, 2002
-
ARCHIVE Olympus: New Reaction/Analysis System FD10
October 7, 2002
-
ARCHIVE Results of Reexamination for 22 Active Ingredients Announced
October 7, 2002
-
ARCHIVE Baxter Transfers Cardiovascular Products to Edwards Lifesciences in Japan
October 7, 2002
-
ARCHIVE DIA Conference on Pharmaceutical Evolution in Asia
October 7, 2002
-
ARCHIVE New Chugai Inaugurated
October 7, 2002
-
ARCHIVE Relief of Lower Back Pain Increases Patients' Satisfaction with Osteoporosis Drugs
October 7, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
October 7, 2002
-
ARCHIVE CORPORATE ROUNDUP NEWS IN BRIEF
October 7, 2002
-
ARCHIVE ENGLISH BOOK
October 7, 2002
-
ARCHIVE Maurer's Healthcare Insight (34)
October 7, 2002
-
ARCHIVE BULLETIN
October 7, 2002
-
ARCHIVE JP Should Be in Greater Harmony with Pharmacopoeias from Other Countries: Seminar
October 7, 2002
-
COMMENTARY Commentary 2 articles
October 7, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…